Zynex (ZYXI) Osake Kurssi
Zynex Kurssi
Viimeisten 19 vuoden aikana Zynexn liikevaihto kasvoi 26,4 % vuodessa ja ylsi 192,35 M USD:een. Osakekohtainen tulos on kasvanut 17,1 % vuodessa viimeisten 19 vuoden aikana. Zynexn nettomarginaali 1,6 % on laskenut verrattuna 11,3 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 1,67 %. Jakosuhde on noin 0 % tuloksesta. Osinko on kasvanut 9,3 % vuodessa viimeisten 4 vuoden aikana.
Zynex osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Zynex liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Zynex -osakkeesta
Zynex Inc's business model revolves around developing, manufacturing, and marketing non-invasive medical devices and accessories. The company specializes in electrotherapy products that aid in pain management, rehabilitation, and physical therapy. Zynex Inc primarily focuses on three key business segments: electrotherapy, neurological diagnostics, and patient monitoring. With a commitment to innovation and quality, Zynex Inc serves healthcare professionals, patients, and medical institutions with its advanced medical technologies. Through this business model, Zynex Inc aims to improve patient outcomes, enhance quality of life, and contribute to the overall advancement of the medical industry.
Zynex Inc is primarily active in the medical device industry.
The main competitors of Zynex Inc in the market include companies such as Medtronic, Abbott Laboratories, and Neurometrix. These companies also specialize in medical devices and technology, providing similar products and services within the healthcare industry. Zynex Inc competes with these companies to capture market share and meet the needs of healthcare professionals and patients.
Zynex Inc is a reputable company with a rich history and background. Founded in 1996, Zynex has consistently grown and established itself as a leader in the medical technology industry. Specializing in electrotherapy devices, the company offers innovative solutions for pain management and rehabilitation. Zynex has successfully developed and commercialized numerous products that have helped improve the lives of patients worldwide. Their commitment to research and development, along with their dedication to customer satisfaction, has garnered them a strong reputation in the market. With a focus on technological advancements and a mission to enhance patient care, Zynex Inc continues to thrive and make a significant impact in the medical device industry.
Zynex Inc, a leading medical technology company, has achieved several significant milestones. The company successfully introduced NeuroMove, its flagship neuro rehabilitation therapy device, which has revolutionized the industry. Zynex Inc also received FDA approval for their innovative Pain Management products, including NexWave and Infinity Plus, providing advanced pain relief solutions to patients. Furthermore, the company expanded its reach across the United States, establishing a strong presence in the healthcare market. Zynex Inc's consistent focus on research and development, coupled with its commitment to improving patient outcomes, has positioned them as a leading player in the medical technology sector.
Zynex Inc is primarily present in the United States of America.
Zynex Inc represents values of innovation, excellence, and patient-centric care in the medical technology industry. With a corporate philosophy focused on delivering high-quality medical devices and exceptional customer service, Zynex Inc strives to enhance the lives of patients through advanced medical solutions. The company is dedicated to continuously innovating and developing state-of-the-art products that improve healthcare outcomes and patient experiences. Zynex Inc's commitment to excellence has made it a trusted name in the industry, providing effective and reliable medical solutions.
8 analyytikkoa arvioi tällä hetkellä Zynex-osaketta: 6 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Zynex-yhtiöltä 101,20 M USD liikevaihtoa ja −0,45 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Zynex-osake noteerataan hintaan 0,05 EUR (0,06 USD).
Zynex-osake (ZYXI) on listattuna 1 pörssissä, muun muassa: NASDAQ (ZYXI).
Zynex Inc is a healthcare company based in the United States that specializes in the development and marketing of medical devices and therapy equipment. The company was founded in 1996 and is headquartered in Lone Tree, Colorado. Zynex offers a wide range of products and services for various medical areas. The core areas of Zynex are electrotherapy, pain therapy, orthopedics, and neurology. In these areas, the company develops and produces medical devices such as electronic pain therapy devices, electromyography-guided therapy systems, neurological therapy devices, and custom-fit orthotic systems. Zynex's electrotherapy devices are used for pain relief and muscle stimulation. The devices are easy to use and can be used at home. The range includes portable muscle stimulation devices that relieve joint, back, or neck pain, as well as transcutaneous electrical nerve stimulation (TENS) devices that enable non-invasive pain treatment. Zynex also offers electromyography-guided therapy systems that are used in the rehabilitation after injuries or surgeries. These systems are specifically tailored to the individual needs of the patient and help restore muscle strength and function. In the field of neurology, Zynex offers devices for the treatment of stroke patients, including direct current stimulation systems and electronic muscle stimulation devices. These devices help improve the motor skills of the patients. Zynex's custom-fit orthotic system is an individually tailored orthosis system that provides protection and support for injuries or conditions. The orthotic systems are made from high-quality materials and are tailored to the individual needs of the patient. In addition to developing and manufacturing medical devices, Zynex also offers medical services, such as conducting electromyography tests and providing patients with orthotic aids. Zynex aims to offer medical products that improve patients' quality of life and contribute to their recovery. The company works closely with medical professionals to develop and launch its products on the market. In summary, Zynex Inc is an innovative and versatile company that specializes in the development and marketing of medical devices and therapy equipment. The company offers its customers a wide range of products and services that are tailored to the individual needs of patients. With its high-quality and effective products, Zynex contributes to people leading better and pain-free lives.
odotettu liikevaihto Zynex on 101,20 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Zynex on −14,59 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Zynex:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,13. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Zynex-osakkeen arvostusta.
Zynex:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,02. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Zynex-osakkeen arvostuskennuslukuna.
Zynex:n Eulpool-laatuscore on 4/10.
Zynex:n ISIN on US98986M1036. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Zynex:n WKN on A0Q5XP. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Zynex:n ticker on ZYXI. Tämä pörssinoteeraus käytetään Zynex-osakkeiden kauppaan pörssissä.
Zynex osake
Zynex vertaisryhmä
Zynex Ticker
Zynex FIGI
Kaikki tunnusluvut ja syvällinen analyysi Zynex:sta
Meidän osakeanalyysimme Zynex-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Zynex:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: